Goldman Sachs raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $41 from $36 and keeps a Neutral rating on the shares. The company reported Q3 EPS topped estimates, posting a beat on Xdemvy net product sales at $48.1M, albeit with somewhat in-line number of vials dispensed, the analyst tells investors in a research note. Tarsus’ commentary on the call focused on the improving outlook for Xdemvy in Q4 and beyond on the back of the recent sales force addition, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals price target raised to $73 from $61 at H.C. Wainwright
- Tarsus Pharmaceuticals price target raised to $65 from $63 at Oppenheimer
- Tarsus Pharmaceuticals Reports Strong Q3 2024 Performance
- Closing Bell Movers: Tetra Tech down 8% after Q4 results, guidance
- Tarsus Pharmaceuticals reports Q3 EPS (61c), consensus (94c)